<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566176</url>
  </required_header>
  <id_info>
    <org_study_id>CP2005-1</org_study_id>
    <nct_id>NCT00566176</nct_id>
  </id_info>
  <brief_title>Sole-Therapy Treatment of Atrial Fibrillation</brief_title>
  <acronym>RESTORE SR II</acronym>
  <official_title>Thoracoscopically-Assisted Epicardial Bilateral Pulmonary Vein Isolations Using the AtriCure Bipolar System and Exclusion of the Left Atrial Appendage for the Treatment of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtriCure, Inc.</source>
  <brief_summary>
    <textblock>
      RESTORE SR II is a feasibility study on the minimally invasive use of the AtriCure Bipolar&#xD;
      System for PV Isolation on a beating heart for the treatment of all types of atrial&#xD;
      fibrillation in a sole therapy operation (not concomitant to another cardiac operation).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2005</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the feasibility of performing this operation by demonstrating the ability to consistently isolate the right and left PVs using this minimally invasive approach.</measure>
    <time_frame>Perioperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary safety endpoint will be determined by assessing the rate of serious adverse events.</measure>
    <time_frame>Discharge/30 Days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical Ablation using the AtriCure Bipolar System</intervention_name>
    <description>Surgical Ablation using the AtriCure Bipolar System</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patient between 18 and 80 years of age&#xD;
&#xD;
          2. Patient with symptomatic AF and failure or intolerance of one or more Class I or Class&#xD;
             III AADs and:&#xD;
&#xD;
               -  Who describes 3 or more symptomatic AF episodes during the 6 month period prior&#xD;
                  to enrollment, with at least 1 electrocardiographically documented episode of AF&#xD;
                  in the 4 months prior to enrollment or,&#xD;
&#xD;
               -  Who has documented AF within the 6 months proceeding enrollment that did not&#xD;
                  terminate spontaneously (including patients in continuous AF) or,&#xD;
&#xD;
               -  Who is unwilling or unable to take anticoagulants, with 3 or more symptomatic&#xD;
                  episodes during the 6 month period prior to enrollment with at least 1&#xD;
                  electrocardiographically documented episode of AF in the 4 months prior to&#xD;
                  enrollment.&#xD;
&#xD;
          3. Left Atrial Size &lt; 6 cm (determined by echocardiography performed within 60 days of&#xD;
             enrollment), unless the LV dysfunction is thought to result (at least in part) from AF&#xD;
&#xD;
          4. Left Ventricular Ejection Fraction â‰¥ 30% (determined by echocardiography performed&#xD;
             within 60 days of enrollment)&#xD;
&#xD;
          5. Patient is willing and able to provide written informed consent.&#xD;
&#xD;
          6. Patient has a life expectancy of at least 2 years.&#xD;
&#xD;
          7. Patient is willing and able to attend the scheduled follow-up visits.&#xD;
&#xD;
          8. Weight &lt; 325 lbs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior cardiac catheter ablation for the treatment of arrhythmia within 4 months&#xD;
&#xD;
          2. Prior cardiac surgery&#xD;
&#xD;
          3. Patients requiring any open heart procedure (e.g. CABG, valve replacement or repair,&#xD;
             atrial septal defect repair, etc.)&#xD;
&#xD;
          4. Class IV NYHA heart failure symptoms, unless these symptoms are considered to be due&#xD;
             to uncontrolled AF&#xD;
&#xD;
          5. Cerebrovascular accident within previous 6 months&#xD;
&#xD;
          6. Known carotid artery stenosis greater than 80%&#xD;
&#xD;
          7. Evidence of significant active infection&#xD;
&#xD;
          8. Patient unable to undergo TEE&#xD;
&#xD;
          9. Pregnant woman&#xD;
&#xD;
         10. Requires anti-arrhythmic drug therapy for the treatment of ventricular arrhythmia&#xD;
&#xD;
         11. Presence of thrombus in the left atrium&#xD;
&#xD;
         12. Patient has co-morbid condition that in the opinion of the investigator poses undue&#xD;
             risk of general anesthesia or port access cardiac surgery&#xD;
&#xD;
         13. Patient is enrolled in another investigational study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Jackman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklamhoma Cardiac Arrythmia Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Edgerton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical City Hospital/Cardio Pulmonary Research Science and Technology Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Community Hospital/Dr. Kiran C. Patel Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Cardiac Arrythmia Research Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center Endovascular Research</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Hospital/Cardio Pulmonary Research Science and Technology Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>AF</keyword>
  <keyword>AFIB</keyword>
  <keyword>racing heart</keyword>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>pvi</keyword>
  <keyword>mini maze</keyword>
  <keyword>maze</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

